Manchester Mgmt. Co. v. Echo Therapeutics, Inc.

297 F. Supp. 3d 451
CourtDistrict Court, S.D. Illinois
DecidedMarch 14, 2018
Docket16 Civ. 9217 (KPF)
StatusPublished
Cited by5 cases

This text of 297 F. Supp. 3d 451 (Manchester Mgmt. Co. v. Echo Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Manchester Mgmt. Co. v. Echo Therapeutics, Inc., 297 F. Supp. 3d 451 (S.D. Ill. 2018).

Opinion

KATHERINE POLK FAILLA, District Judge:

On November 29, 2016, Plaintiffs Manchester Management Company, LLC, Manchester Alpha, L.P., JEB Partners, L.P., James E. Besser, and Donald Besser (collectively, "Plaintiffs") filed a complaint in this District along with an ex parte application for a temporary restraining order ("TRO"). In their complaint, Plaintiffs claimed that they had been misled in their purchase of securities in Echo Therapeutics, Inc. ("Echo"); they laid blame for that deception at the feet of three individuals associated with Echo-cousins Michael and Shepard Goldberg and Michael's son Alec (together with Echo, the "Echo Defendants")-as well as the hedge fund Platinum Management (NY) LLC ("Platinum Management"), its co-owners Mark Nordlicht and Bernard Fuchs (with Platinum Management, the "Platinum Defendants"), and a Chinese company, Medical Technologies Innovation Asia, Ltd. ("MTIA") (with the Echo and Platinum Defendants, "Defendants"). In their request for injunctive relief, Plaintiffs claimed that a contemplated transaction between Echo and MTIA that was scheduled to close imminently would result in the improper expropriation to China of Echo's intellectual property.

The Court granted the application for a TRO and, after expedited discovery, convened a two-day-long hearing (the "Hearing") on Plaintiffs' motion for a preliminary injunction on December 8 and 9, 2016. After concluding, on the concededly incomplete record before it, that Plaintiffs had not met their burden of demonstrating irreparable harm or a likelihood of success on the merits, the Court denied Plaintiffs' motion. Ten days later, before Defendants responded to the complaint, Plaintiffs voluntarily dismissed their lawsuit pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i).

The Echo Defendants contend that Plaintiffs' lawsuit was a precipitous-indeed, vexatious-action, whose ruinous consequences cannot be remedied merely by its dismissal. In consequence, the Echo Defendants seek sanctions under the mandatory review provision of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), 15 U.S.C. § 78u-4(c)(1), Federal Rule of Civil Procedure 11, 28 U.S.C. § 1927, and the Court's inherent power. The Court understands Echo's frustrations, but cannot find on this record that the lawsuit was either frivolous or vexatious. Accordingly, and as detailed in the remainder of this Opinion, the Court denies the Echo Defendants' motion.

BACKGROUND1

A. Factual Background

Because this motion focuses on Plaintiffs' conduct in this litigation, the Court *455will address only briefly the parties' interactions before November 29, 2016. Echo is a medical device company that focuses on non-invasive continuous glucose monitoring ("CGM") and associated technologies. (Compl. ¶ 1). In or about December 2013, Echo entered into a License, Development and Commercialization Agreement (the "Licensing Agreement") with MTIA, pursuant to which Echo granted MTIA rights to develop, manufacture, market and distribute Echo's CGM system in China. (Id. at ¶ 19).2 To a degree disputed vigorously by the parties, the Licensing Agreement permitted transfer of certain of Echo's intellectual property to MTIA, though Echo retained ownership over such property. (Id. ).

Also in December 2013, Echo and several Platinum-related entities entered into a Securities Purchase Agreement (the "SPA") for the purchase of more than 1.8 million shares of Echo stock. (Compl. ¶ 21). Platinum obtained a seat on Echo's Board of Directors, and nominated Dr. Michael Goldberg, who later became Board Chairman in February 2015. (Id. at ¶ 24 n.7). Michael's cousin Shepard Goldberg was elected to the Board in June 2014 after a contentious proxy fight. (Id. at ¶ 25).3 In September and December of 2014, various Platinum-related entities infused cash into Echo. (Id. at ¶¶ 27-28, 31).

In January 2016, NASDAQ initiated procedures to delist Echo; stated reasons included the failure to meet stockholders' equity requirements and the failure to hold an annual stockholders' meeting. (Compl. ¶ 43). In that month, and then again in May 2016, Plaintiffs purchased a total of $800,000 of Echo's 10% senior secured convertible notes (the "Notes") through a Confidential Private Placement Memorandum (the "PPM"). (Id. at ¶¶ 3, 11-13). As a result of their purchases, Plaintiffs obtained "a security interest in the assets of Echo, including, but not limited to, Echo's intellectual property." (Id. at ¶ 12).

Plaintiffs observe that various Platinum-related entities were subject to civil and criminal investigations and/or litigation in 2016. (See, e.g. , Compl. ¶¶ 6-10, 45-46). This turmoil, it is alleged, then spread to Echo: "Since in or about July 2016 to date, Echo has been in a state of constant and acute financial distress." (Id. at 48). Echo's *456alleged reactions to this distress resulted in Plaintiffs' lawsuit.

B. Procedural Background

1. The Complaint and the TRO

Plaintiffs filed the Complaint on November 29, 2016. The key factual assertions were as follows:

As set forth herein, the Platinum Defendants, Echo, Michael Goldberg ("M. Goldberg") and Shepard Goldberg (''S. Goldberg") made material misrepresentations and/or omissions in connection with Echo's offer and sale of $6,000,000 of 10% senior secured convertible notes (the "Notes"), of which Plaintiffs purchased $800,000. These misrepresentations and/or omissions occurred through the means of a Confidential Private Placement Memorandum ("PPM"). In the PPM, Defendants intentionally and carefully concealed that Echo's business and board of directors were under the direct and absolute control of the Platinum Defendants in violation of Federal Securities Laws. Through the Platinum Defendants' undisclosed dominion over Echo, the Defendants have and continue to plunder Echo's trade secrets, including its state-of-the-art CGM technology in violation of the Economic Espionage Act of 1996 (as amended by the Defend Trade Secrets Act of 2016).
* * *
The Goldberg Defendants, in their positions of control over Echo's board of directors, have ensured that the Platinum Defendants' instructions to plunder the assets of Echo were carried out. To this day, the Platinum Defendants, both directly and through the Goldberg Defendants, are proceeding to plunder Echo's trade secrets by providing them to Defendant Medical Technologies Innovation Asia, Ltd. ("MTIA"), which has substantial ties to the Platinum Defendants and the Goldberg Defendants, the full extent of which is not yet known.

(Compl. ¶¶ 3, 5).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
297 F. Supp. 3d 451, Counsel Stack Legal Research, https://law.counselstack.com/opinion/manchester-mgmt-co-v-echo-therapeutics-inc-ilsd-2018.